TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of “Buy” from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has earned an average recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $8.50.

A number of equities analysts have recently issued reports on TCRX shares. Morgan Stanley reissued an “overweight” rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Friday, March 14th. Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Wedbush reiterated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $9.00 price target on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Finally, HC Wainwright decreased their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday.

Hedge Funds Weigh In On TScan Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Lynx1 Capital Management LP grew its stake in shares of TScan Therapeutics by 2.5% during the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock valued at $16,286,000 after purchasing an additional 132,747 shares during the last quarter. Geode Capital Management LLC lifted its holdings in TScan Therapeutics by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock worth $4,849,000 after buying an additional 72,967 shares in the last quarter. abrdn plc boosted its position in TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after buying an additional 512,049 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock valued at $851,000 after buying an additional 145,731 shares during the period. Finally, Tocqueville Asset Management L.P. raised its position in shares of TScan Therapeutics by 26.8% during the fourth quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company’s stock worth $793,000 after acquiring an additional 55,140 shares during the last quarter. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Stock Down 6.9 %

Shares of TCRX stock opened at $1.29 on Friday. TScan Therapeutics has a one year low of $1.02 and a one year high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The stock has a fifty day moving average price of $1.49 and a 200 day moving average price of $2.72. The stock has a market cap of $72.72 million, a P/E ratio of -1.21 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. Analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.